{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:12:05Z","timestamp":1789200725761,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.esmoop.2024.103709","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T18:42:36Z","timestamp":1726857756000},"page":"103709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05"],"prefix":"10.1016","volume":"9","author":[{"given":"T.-Y.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-3620","authenticated-orcid":false,"given":"J.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.J.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.G.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5651-7939","authenticated-orcid":false,"given":"Y.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.-W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-5954","authenticated-orcid":false,"given":"H.","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.L.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-1997","authenticated-orcid":false,"given":"T.W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-7848","authenticated-orcid":false,"given":"D.Y.","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2024.103709_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.103709_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00002","article-title":"Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD Anderson Precision Medicine Study","author":"Tsimberidou","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103709_bib3","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103709_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41698-021-00159-2","article-title":"Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study","volume":"5","author":"Tsimberidou","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib5","article-title":"Molecular profiling-based assignment of cancer therapy (NCI-MPACT): a randomized multicenter phase II trial","volume":"5","author":"Chen","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2024.103709_bib6","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.19.03010","article-title":"Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","volume":"38","author":"Flaherty","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2024.103709_bib7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib8","article-title":"Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"PO.18.00122","author":"Mangat","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"7776","key":"10.1016\/j.esmoop.2024.103709_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The drug rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2024.103709_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2024.103709_bib11","article-title":"Impact of molecular tumor board on the clinical management of patients with cancer","volume":"8","author":"Behel","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103709_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s43018-022-00332-x","article-title":"The molecular tumor board portal supports clinical decisions and automated reporting for precision oncology","volume":"3","author":"Tamborero","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103709_bib13","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103709_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2021.1115","article-title":"Recommendations for the use of next-generation sequencing and the molecular tumor board for patients with advanced cancer: a report from KSMO and KCSG Precision Medicine Networking Group","volume":"54","author":"Yoon","year":"2022","journal-title":"Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103709_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103709_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103709_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13073-016-0364-2","article-title":"Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT\/COMPACT trial","volume":"8","author":"Stockley","year":"2016","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103709_bib18","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103709_bib19","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol"},{"issue":"7619","key":"10.1016\/j.esmoop.2024.103709_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/537S63a","article-title":"Perspective: the precision-oncology illusion","volume":"537","author":"Prasad","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103709_bib21","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1038\/s41467-021-26213-y","article-title":"Cancer gene mutation frequencies for the U.S. population","volume":"12","author":"Mendiratta","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103709_bib22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/2159-8290.CD-21-1064","article-title":"Genomic landscape and clinical utility in Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER Program","volume":"12","author":"Park","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103709_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"33","key":"10.1016\/j.esmoop.2024.103709_bib24","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103709_bib25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103709_bib26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41591-019-0380-z","article-title":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","volume":"25","author":"Rothwell","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103709_bib27","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103709_bib28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11523-020-00753-7","article-title":"Cetuximab in patients with breast cancer, non-small cell lung cancer, and ovarian cancer without KRAS, NRAS, or BRAF mutations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"15","author":"Fisher","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib29","article-title":"Cobimetinib plus vemurafenib in patients with colorectal cancer with BRAF mutations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"6","author":"Klute","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib30","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"7","author":"Rohatgi","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib31","article-title":"Olaparib in patients with metastatic prostate cancer with BRCA1\/2 mutation: results from the TAPUR study","volume":"7","author":"Yang","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/PO.20.00037","article-title":"Palbociclib in patients with non-small-cell lung cancer with CDKN2A alterations: results from the Targeted Agent and Profiling Utilization Registry study","volume":"4","author":"Ahn","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00124","article-title":"Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the Targeted Agent and Profiling Utilization Registry study","volume":"3","author":"Al Baghdadi","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib34","article-title":"Palbociclib in patients with soft tissue sarcoma with CDK4 amplifications: results from the Targeted Agent and Profiling Utilization Registry study","volume":"8","author":"Schuetze","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103709_bib35","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.20.02923","article-title":"Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"39","author":"Alva","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib36","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR Study","volume":"6","author":"Gupta","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib37","article-title":"Pertuzumab plus trastuzumab in patients with endometrial cancer with ERBB2\/3 amplification, overexpression, or mutation: results from the TAPUR study","volume":"7","author":"Ahn","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib38","article-title":"Pertuzumab plus trastuzumab in patients with lung cancer with ERBB2 mutation or amplification: results from the Targeted Agent and Profiling Utilization Registry study","volume":"7","author":"Ganti","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103709_bib39","article-title":"Regorafenib in patients with solid tumors with BRAF alterations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"8","author":"Sahai","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103709_bib40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11523-020-00752-8","article-title":"Sunitinib in patients with metastatic colorectal cancer (mCRC) with FLT-3 amplification: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"15","author":"Al","year":"2020","journal-title":"Target Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2024.103709_bib41","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1200\/JCO.23.00702","article-title":"Pembrolizumab in patients with tumors with high tumor mutational burden: results from the Targeted Agent and Profiling Utilization Registry study","volume":"41","author":"Duvivier","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T23:11:36Z","timestamp":1729811496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2059702924014790"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103709","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103709"}}